Table 1 Clinical characteristics of the study population
| Â | Tofacitinib (n = 161) | Baricitinib (n = 81) | P value |
|---|---|---|---|
Female, n (%) | 133 (82.6) | 68 (84.0) | 0.857 |
Age (years) | 67 [58–73] | 66 [56–74] | 0.667 |
Duration of RA (years) | 12 [6–18] | 11 [4–18] | 0.243 |
Concomitant MTX use, n (%) | 109 (67.7) | 37 (45.7) | 0.001 |
Mean MTX dose (mg/week) | 8.62 ± 2.49 | 8.05 ± 2.69 | 0.427 |
Concomitant oral steroid use, n (%) | 86 (53.4) | 38 (46.9) | 0.345 |
Mean oral steroid dose (mg/day) | 4.80 ± 2.72 | 4.80 ± 3.08 | 0.844 |
ACPA positive, n (%) | 124 (77.0) | 65 (80.2) | 0.624 |
RF positive, n (%) | 122 (75.8) | 70 (86.4) | 0.064 |
No prior use of b/tsDMARDs, n (%) | 37 (23.0) | 18 (22.2) | > 0.999 |
Number of previous use of b/tsDMARDs | 2.00 [1.00–3.00] | 2.00 [1.00–3.00] | 0.968 |
DAS28-ESR | 5.17 [4.08–6.11] | 5.13 [4.21–5.98] | 0.622 |
SDAI | 20 [14–32] | 19 [14–29] | 0.507 |
CDAI | 19 [12–30] | 18 [12–27] | 0.497 |
mHAQ | 0.60 [0.1–1.3] | 0.62 [0.12–1.38] | 0.372 |